Company Overview and News

0
Allergan, Molecular Partners eye drug meets main goal in two studies

19h reuters
(Reuters) - Allergan Plc and Molecular Partners AG said on Thursday their treatment for age-related macular degeneration met the main goal in two late-stage studies.
RHHVF AGN AGN.PRA RHHBY ACT RHHBF

0
Allergan, Molecular Partners eye drug meets main goal in two studies - Channel NewsAsia

19h channelnewsasia
Allergan Plc and Molecular Partners AG said on Thursday their treatment for age-related macular degeneration met the main goal in two late-stage studies.
RHHVF AGN AGN.PRA RHHBY ACT RHHBF

0
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

2018-07-18 zacks
Roche Holding AG (RHHBY - Free Report) announced that the FDA has granted breakthrough therapy designation to its immuno-oncology drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced hepatocellular carcinoma (HCC).
RHHVF EXEL VNDA RHHBY ILMN RHHBF

29
Superbugs Win Another Round as Big Pharma Leaves Antibiotics - Bloomberg

2018-07-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AZN PRTK MDCO MTFB MLNT ACT GSK RHHBF MTFBF RHHVF AGN AGN.PRA RHHBY NVS GSK AKAO

52
Pharmaceutical companies ignore Donald Trump and raise drug prices

2018-07-12 theage.com.au
US President Donald Trump bragged may have bragged about convincing Pfizer to hold off on price increases, but the pharmaceutical giant isn't the only drug company looking to charge more for its products.
ACOR RHHVF RHHBY AYTUZ AYTU RHHBF

52
Pharmaceutical companies ignore Donald Trump and raise drug prices

2018-07-12 smh.com.au
US President Donald Trump bragged may have bragged about convincing Pfizer to hold off on price increases, but the pharmaceutical giant isn't the only drug company looking to charge more for its products.
ACOR RHHVF RHHBY AYTUZ AYTU RHHBF

54
Many Drugmakers Ignore Trump—and Raise Prices Anyway - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ CELGZ AYTUZ ENL PFIZER RHHBF ACOR RHHVF CELG RHHBY AYTU 500680 PFE ENDP

2
Trump Says Pfizer Is Rolling Back Drug ‘Price Hikes’ - Bloomberg

2018-07-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ RHHVF GILD RHHBY NVS 500680 PFE PFIZER RHHBF

1
Drugmakers Cancel Price Hikes After California Law Takes Effect - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
RHHVF GILD RHHBY NVS RHHBF

1
CTI Biopharma's cancer drug fails late-stage trial - Channel NewsAsia

2018-07-09 channelnewsasia
REUTERS: CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial.
RHHVF RHHBY CTIC CTI RHHBF

1
UPDATE 1-CTI Biopharma's cancer drug fails late-stage trial

2018-07-09 reuters
(Reuters) - CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial.
RHHVF RHHBY CTIC CTI RHHBF

22
Forty Seven IPO: Google Has A Stake, But Other Competitors Trade At Lower Valuations

2018-07-06 seekingalpha
Entities affiliated with Google own 5.2% stake in the company. Clients of Wellington Management Company have 6.8% stake as well.
ORPHF ABT MKGAF AMGN CELGZ GILD SURF GOOG TRIL ABT RHHBF ARTH RHHVF MKGAY MRK CELG RHHBY FTSV PDLI

0
Should Value Investors Consider Roche Holding (RHHBY) Stock?

2018-07-05 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
RHHVF RHHBY RHHBF

1
Rare Cancer Challenge: Genomic Screening and Clinical Trials

2018-07-05 biospace
Although different countries define them differently, in the U.S., a rare cancer is defined as six or less out of 100,000 people having that cancer. European regulatory agencies tend to classify a rare cancer as prevalence of fewer than five cases out of 10,000. The International Rare Cancers Initiative (IRCI) defines a rare cancer as a cancer with an incidence of three or fewer newly diagnosed people out of a population of 100,000 pear years.
RHHVF LOXO RHHBY FMI RHHBF

15
Roche Family Fortune Built on Cough Syrup Helps Shape Swiss City - Bloomberg

2018-06-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
RHHVF RHHBY RHHBF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: H69293217